These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23515714)

  • 1. Assessment of cardiovascular disease risk in patients with schizophrenia spectrum disorders in German psychiatric hospitals: results of the pharmacoepidemiologic CATS study.
    Deuschle M; Paul F; Brosz M; Bergemann N; Franz M; Kammerer-Ciernioch J; Lautenschlager M; Lederbogen F; Roesch-Ely D; Weisbrod M; Kahl KG; Reichmann J; Gross J; Umbreit J
    Soc Psychiatry Psychiatr Epidemiol; 2013 Aug; 48(8):1283-8. PubMed ID: 23515714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic syndrome and cardiovascular risk among institutionalized patients with schizophrenia receiving long term tertiary care.
    Seow LS; Chong SA; Wang P; Shafie S; Ong HL; Subramaniam M
    Compr Psychiatry; 2017 Apr; 74():196-203. PubMed ID: 28214752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study.
    Correll CU; Robinson DG; Schooler NR; Brunette MF; Mueser KT; Rosenheck RA; Marcy P; Addington J; Estroff SE; Robinson J; Penn DL; Azrin S; Goldstein A; Severe J; Heinssen R; Kane JM
    JAMA Psychiatry; 2014 Dec; 71(12):1350-63. PubMed ID: 25321337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The correlation between waist circumference and ESC cardiovascular risk score: data from the German metabolic and cardiovascular risk project (GEMCAS).
    Schunkert H; Moebus S; Hanisch J; Bramlage P; Steinhagen-Thiessen E; Hauner H; Weil J; Wasem J; Jöckel KH
    Clin Res Cardiol; 2008 Nov; 97(11):827-35. PubMed ID: 18648725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders: a cross-sectional study.
    Bressington D; Mui J; Tse ML; Gray R; Cheung EF; Chien WT
    BMC Psychiatry; 2016 Nov; 16(1):411. PubMed ID: 27863522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic syndrome and cardiovascular risk among patients with schizophrenia receiving antipsychotics in Malaysia.
    Said MA; Sulaiman AH; Habil MH; Das S; Bakar AK; Yusoff RM; Loo TH; Bakar SA
    Singapore Med J; 2012 Dec; 53(12):801-7. PubMed ID: 23268153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic syndrome in schizophrenia: a comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India.
    Pallava A; Chadda RK; Sood M; Lakshmy R
    Nord J Psychiatry; 2012 Jun; 66(3):215-21. PubMed ID: 22017264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of cannabis use on body mass, fasting glucose and lipids during the first 12 months of treatment in schizophrenia spectrum disorders.
    Scheffler F; Kilian S; Chiliza B; Asmal L; Phahladira L; du Plessis S; Kidd M; Murray RM; Di Forti M; Seedat S; Emsley R
    Schizophr Res; 2018 Sep; 199():90-95. PubMed ID: 29519756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.
    Falissard B; Mauri M; Shaw K; Wetterling T; Doble A; Giudicelli A; De Hert M
    Int Clin Psychopharmacol; 2011 Nov; 26(6):291-302. PubMed ID: 21876442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics.
    Krane-Gartiser K; Breum L; Glümrr C; Linneberg A; Madsen M; Køster A; Jepsen PW; Fink-Jensen A
    Nord J Psychiatry; 2011 Oct; 65(5):345-52. PubMed ID: 21428861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Retrospective Chart Review of Screening on the Prevalence of Metabolic Syndrome (MetS) in an Irish Community Mental Health Service.
    Cocoman AM; Gallagher D
    Issues Ment Health Nurs; 2019 Oct; 40(10):895-901. PubMed ID: 31295053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in body mass and metabolic profiles in patients with first-episode schizophrenia treated for 12 months with a first-generation antipsychotic.
    Chiliza B; Asmal L; Oosthuizen P; van Niekerk E; Erasmus R; Kidd M; Malhotra A; Emsley R
    Eur Psychiatry; 2015 Feb; 30(2):277-83. PubMed ID: 25577186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study.
    Arango C; Bobes J; Aranda P; Carmena R; Garcia-Garcia M; Rejas J;
    Schizophr Res; 2008 Sep; 104(1-3):1-12. PubMed ID: 18606526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations between clinical and psychosocial factors and metabolic and cardiovascular risk factors in overweight patients with schizophrenia spectrum disorders - Baseline and two-years findings from the CHANGE trial.
    Storch Jakobsen A; Speyer H; Nørgaard HCB; Hjorthøj C; Krogh J; Mors O; Nordentoft M
    Schizophr Res; 2018 Sep; 199():96-102. PubMed ID: 29501386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of cardiovascular risk in an Italian psychiatric outpatient sample: A chart review of patients treated with second-generation antipsychotics.
    Severi E; Ferrara M; Tedeschini E; Vacca F; Mungai F; Amendolara R; Baccari F; Starace F
    Int J Ment Health Nurs; 2018 Jun; 27(3):1002-1008. PubMed ID: 29197134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
    Jin H; Shih PA; Golshan S; Mudaliar S; Henry R; Glorioso DK; Arndt S; Kraemer HC; Jeste DV
    J Clin Psychiatry; 2013 Jan; 74(1):10-8. PubMed ID: 23218100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between C-reactive protein and homocysteine with the subcomponents of metabolic syndrome in stable patients with bipolar disorder and schizophrenia.
    Vuksan-Cusa B; Sagud M; Jakovljevic M; Peles AM; Jaksic N; Mihaljevic S; Zivkovic M; Mikulic SK; Jevtovic S
    Nord J Psychiatry; 2013 Oct; 67(5):320-5. PubMed ID: 23228159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.
    Meyer JM; Nasrallah HA; McEvoy JP; Goff DC; Davis SM; Chakos M; Patel JK; Keefe RS; Stroup TS; Lieberman JA
    Schizophr Res; 2005 Dec; 80(1):9-18. PubMed ID: 16125372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.
    McEvoy JP; Meyer JM; Goff DC; Nasrallah HA; Davis SM; Sullivan L; Meltzer HY; Hsiao J; Scott Stroup T; Lieberman JA
    Schizophr Res; 2005 Dec; 80(1):19-32. PubMed ID: 16137860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.